Press Releases: 2019

A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

April 30, 2019
ISA's phase 2 trial with lead product ISA101
Read more
A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

April 18, 2019
ecancer interview ISA's Chief Science Officer Prof. Dr. Kees Melief
Read more
Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

April 02, 2019
Cornelis J. M. 'Kees' Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the...
Read more
CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

March 28, 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Read more
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--...
Read more
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

Home > Press Releases > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds